secwatch.observer — SEC 8-K summary
======================================

Issuer:     MERIT MEDICAL SYSTEMS INC (MMSI)
CIK:        0000856982
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0000856982-25-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merit Medical Q2 revenue up 13.2% to $382.5M; non-GAAP EPS $1.01, up 9.8%; appoints new CEO
--------------------------------------------------------------------------------

- Revenue $382.5M, +13.2% YoY; constant-currency revenue +12.5%, organic constant-currency +6.7%.
- GAAP EPS $0.54 (-11.6%), non-GAAP EPS $1.01 (+9.8%); GAAP operating margin 12.3% vs 13.6% prior year.
- Non-GAAP operating margin improved to 21.2% from 20.1%; free cash flow $89.1M in H1 2025, +8.1%.
- Acquired Biolife (StatSeal/WoundSeal hemostatic devices); no transaction value disclosed.
- Martha Aronson named President & CEO, effective Oct 3, 2025; Fred Lampropoulos becomes Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/856982/000085698225000045/0000856982-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/856982/000085698225000045/mmsi-20250730x8k.htm
  HTML page:      https://secwatch.observer/filing/0000856982-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer